{
  "slug": "dual-target-rnai-pipeline-2026",
  "topic": "双靶点RNAi药物研发进展和国内外在研管线",
  "report_title": "双靶点 RNAi 药物工艺图谱与上游供应链机会研究",
  "report_subtitle": "近 5 年全球在研管线的合成、偶联与酶催化技术路径解构（2021–2026）",
  "author": "Deep Research 系统",
  "date": "2026-04-21",
  "version": "1.0",
  "type": "综述",
  "confidentiality": "机密 | 仅供内部决策使用",
  "audience": "研发团队（上游供应链 / 工业用酶 / 无细胞表达 / 固定化酶催化方向）",
  "time_range": "近 5 年（2021-01 至 2026-04）",
  "geography": "全球对比（中美欧日为主）",
  "core_questions": [
    "近 5 年全球与中国在研的双靶点 RNAi 药物管线有哪些？分别采用何种靶点组合、技术平台与开发阶段？",
    "双靶点 siRNA 的分子设计路径（串联/偶联/cocktail/多价支架）有哪些？各自工艺差异与关键壁垒是什么？",
    "双靶点 siRNA 的合成工艺（固相/液相/酶法/无细胞表达）和偶联化学（GalNAc、多价簇、支架连接）在各家管线中的实现方式有何不同？",
    "序列合成、偶联化学、纯化等环节上，上游供应链（工业用酶原料、固定化酶催化、无细胞表达体系、亚磷酰胺单体、GalNAc 配体、固相载体等）存在哪些国产替代与卡位机会？",
    "从工艺复杂度与规模化成本角度，哪些双靶点 RNAi 技术路线最有可能率先走向商业化？对应的上游供应机会窗口与切入点是什么？"
  ],
  "comparison_targets": [
    "Alnylam Pharmaceuticals",
    "Arrowhead Pharmaceuticals",
    "Silence Therapeutics",
    "Dicerna / Novo Nordisk",
    "Ionis (siRNA 相关项目)",
    "瑞博生物 (Ribo Life Science)",
    "舶望制药 (Argo Biopharma)",
    "大睿生物 (Sirnaomics / Da Rui)",
    "圣诺制药 (Sirnaomics)",
    "悦康药业 / 君圣泰 / 石药 / 恒瑞 等国内 siRNA 玩家",
    "双靶点 siRNA cocktail 与多价 siRNA 支架相关项目"
  ],
  "exclusions": [
    "不展开讨论具体适应症的临床有效性与安全性细节（临床进度仅作为管线标签使用）",
    "不涉及 mRNA / ASO / saRNA / 基因编辑等非 siRNA 模态的工艺细节（仅在对比位置点到为止）",
    "不做市场容量 / 销售预测 / 估值分析（报告面向上游供应链而非投资人）",
    "不展开疾病机制与药理学讨论"
  ],
  "word_budget_mode": "auto",
  "target_words_zh": 21000,
  "target_words_en": 15000,
  "min_words_zh": 17000,
  "min_words_en": 12000,
  "disclaimer": "本报告基于公开信息与 AI 辅助研究生成，仅供参考，不构成投资或医疗建议。",
  "work_language": "en",
  "output_language": "zh",
  "phase1": {
    "status": "approved",
    "approved": true,
    "approved_at": "2026-04-21T05:42:34Z",
    "approved_note": "User implicitly approved by executing /dr-research",
    "framework_path": "projects/dual-target-rnai-pipeline-2026/phase1/framework.md",
    "initial_scan_path": "projects/dual-target-rnai-pipeline-2026/phase1/initial-scan.md",
    "initial_scan_index_path": "projects/dual-target-rnai-pipeline-2026/phase1/initial-scan-index.md",
    "chapter_count": 10,
    "revision_note": "v2: 按用户反馈重构 — 拆出 Ch6 (固定化酶) 与 Ch7 (QC 酶) 独立章；Ch9 改为 FDA/NMPA/ICH 针对性监管分析（BIOSECURE 仅一句话背景）；字数升档至 15000 EN / 21000 ZH；每章增 Technical Hooks 字段便于专家判断真假机会；初扫 63 条信源输出为 initial-scan-index.md 供 Phase 2 pickup。",
    "central_thesis_en": "The true competitive frontier of dual-target RNAi is not the second siRNA strand but the manufacturing stack beneath it — multivalent GalNAc assembly, enzymatic ligation, immobilized biocatalysis, and the quietly scarce GMP-grade QC enzymes are the choke points. Four upstream nodes (specialty phosphoramidite monomers, high-load solid supports, immobilized glycosyl-transfer biocatalysis, QC enzymes) concentrate most of the opportunity for suppliers who can simultaneously meet NMPA 2026 chemoenzymatic guidance and FDA/ICH Q11-Q13 expectations.",
    "central_thesis_zh": "双靶点 RNAi 的真正竞争前沿不是'加一条 siRNA 链'，而是其下的制造栈 — 多价 GalNAc 组装、酶法连接、固定化生物催化，以及常被忽视却持续短缺的 GMP 级 QC 酶。机会集中在四个上游环节：专用亚磷酰胺单体、高载量固相载体、固定化糖基转移/酯化生物催化、寡核苷酸 QC 酶；能同时满足中国 NMPA 2026 化学酶连指导原则与 FDA/ICH Q11-Q13 体系要求的供应商，将获取最大的结构性红利。",
    "chapter_quotas_en": [
      {
        "index": 1,
        "title_en": "Why the Second Strand Matters Less Than the Stack Beneath It",
        "title_zh": "双靶点的真正战场不在'加第二条链'，而在其下的制造栈",
        "en_words": 1050,
        "priority": "intro"
      },
      {
        "index": 2,
        "title_en": "Dual-Target Design Space Has Already Bifurcated into Four Paradigms, Each with a Different Process Signature",
        "title_zh": "双靶点设计空间已分化为四种范式，每种都带出一条工艺签名",
        "en_words": 1500,
        "priority": "P0"
      },
      {
        "index": 3,
        "title_en": "The Global Pipeline Is Denser than the Headlines Suggest, but China Is Adding Assets Faster than Anyone Else",
        "title_zh": "全球管线比头条更密，但中国正在以最快速度堆积资产",
        "en_words": 1500,
        "priority": "P0"
      },
      {
        "index": 4,
        "title_en": "Solid-Phase Remains the Default, but the Competitive Edge Is Shifting to Liquid-Phase and Enzymatic Ligation",
        "title_zh": "固相合成仍是默认路线，但竞争优势正在向液相与酶法连接迁移",
        "en_words": 1800,
        "priority": "P0"
      },
      {
        "index": 5,
        "title_en": "Multivalent GalNAc Cluster Chemistry: How the Industry Assembles Three-to-Seven Sugars onto a Single Oligo",
        "title_zh": "多价 GalNAc 簇化学：行业如何把 3-7 个糖装到同一条寡核苷酸上",
        "en_words": 1800,
        "priority": "P0"
      },
      {
        "index": 6,
        "title_en": "Immobilized Biocatalysis Enters the GalNAc-Conjugation Pipeline — From Lab Curiosity to GMP Candidate",
        "title_zh": "固定化生物催化进入 GalNAc 偶联流水线 — 从实验室新奇到 GMP 候选",
        "en_words": 1650,
        "priority": "P0"
      },
      {
        "index": 7,
        "title_en": "QC Enzymes and Process-Analytical Biocatalysts: The Quietly Scarce Third Pillar",
        "title_zh": "QC 酶与工艺分析用生物催化剂：被忽视却紧缺的第三支柱",
        "en_words": 1500,
        "priority": "P0"
      },
      {
        "index": 8,
        "title_en": "Four Upstream Choke Points Define the Opportunity Map",
        "title_zh": "四个上游咽喉点定义了机会图谱",
        "en_words": 1650,
        "priority": "P0"
      },
      {
        "index": 9,
        "title_en": "Regulatory Vectors Reshaping the Supply Chain: NMPA Chemoenzymatic Guidance, FDA Oligonucleotide CMC Signals, ICH Q11/Q13",
        "title_zh": "重塑供应链的监管向量：NMPA 化学酶连指导原则、FDA 寡核苷酸 CMC 信号、ICH Q11/Q13",
        "en_words": 1200,
        "priority": "P1"
      },
      {
        "index": 10,
        "title_en": "Conclusions and Upstream Action Priorities, with Technical Thresholds",
        "title_zh": "结论与上游行动优先级（附技术门槛）",
        "en_words": 1350,
        "priority": "conclusion"
      }
    ],
    "total_en_quota": 15000,
    "total_zh_quota_est": 21000,
    "source_count": 63,
    "source_tier_distribution": {
      "tier_1": 27,
      "tier_2": 36
    },
    "phase2_search_gaps": [
      "FDA 寡核苷酸 CMC 指导原则原文",
      "ICH Q3D Cu PDE 具体数值（原文）",
      "ICH Q13 continuous manufacturing 对寡核苷酸酶法合成的适用性",
      "Vazyme / Yeasen / Sangon 等国内 QC 酶产品线与 GMP 认证状态",
      "瑞博 / 舶望 / 圣因 / 必贝特 CNIPA 中文专利说明书",
      "TIDES 2024-2025 会议摘要（Codexis ECO / Nitto CPOS / Hongene 工艺披露）",
      "GreenLight Biosciences 当前资产归属状态"
    ]
  },
  "phase2": {
    "status": "completed",
    "started_at": "2026-04-21T05:42:34Z",
    "completed_at": "2026-04-21T09:30:00Z",
    "current_batch": 5,
    "batches": [
      {
        "batch": 1,
        "chapters": [
          1
        ],
        "note": "Intro chapter — solo"
      },
      {
        "batch": 2,
        "chapters": [
          2,
          3,
          4
        ],
        "note": "Design paradigms + Pipeline + Synthesis"
      },
      {
        "batch": 3,
        "chapters": [
          5,
          6,
          7
        ],
        "note": "GalNAc chemistry + Immobilized biocatalysis + QC enzymes"
      },
      {
        "batch": 4,
        "chapters": [
          8,
          9
        ],
        "note": "Choke points + Regulatory"
      },
      {
        "batch": 5,
        "chapters": [
          10
        ],
        "note": "Conclusion chapter — solo"
      }
    ],
    "chapters": [
      {
        "index": 1,
        "status": "verified",
        "en_words_actual": 1124,
        "en_words_quota": 1050,
        "sources_new": 10,
        "unverified": 2,
        "critical": 1,
        "actual_words": 1124,
        "sources_count": 15
      },
      {
        "index": 2,
        "status": "verified",
        "en_words_quota": 1500,
        "actual_words": 1551,
        "sources_count": 18,
        "unverified_count": 0,
        "verified_at": "2026-04-21T06:33:54.794537Z"
      },
      {
        "index": 3,
        "status": "verified",
        "en_words_quota": 1500,
        "actual_words": 1586,
        "sources_count": 17,
        "unverified_count": 0,
        "verified_at": "2026-04-21T06:33:54.794537Z"
      },
      {
        "index": 4,
        "status": "verified",
        "en_words_quota": 1800,
        "actual_words": 2113,
        "sources_count": 21,
        "unverified_count": 0,
        "verified_at": "2026-04-21T06:33:54.794537Z"
      },
      {
        "index": 5,
        "status": "verified",
        "en_words_quota": 1800,
        "actual_words": 1701,
        "sources_count": 18,
        "unverified_count": 2,
        "critical_count": 1,
        "verified_at": "2026-04-21T07:30:00Z",
        "verifier_verdict": "PASS-WITH-NOTES",
        "verifier_notes": "Cu PDE calculation needs correction (should use 30 µg/day parenteral); SPAAC above 500g threshold unsupported; non-classical GalNAc displays need acknowledgment"
      },
      {
        "index": 6,
        "status": "verified",
        "en_words_quota": 1650,
        "actual_words": 1666,
        "sources_count": 15,
        "unverified_count": 2,
        "critical_count": 1,
        "verified_at": "2026-04-21T07:30:00Z",
        "verifier_verdict": "PASS-WITH-NOTES",
        "verifier_notes": "CRITICAL: ECO scope limited to strand synthesis/ligation, NOT GalNAc conjugation; GT cascade TRL downgraded to 4-5; 'documentation-only gap' claim too strong"
      },
      {
        "index": 7,
        "status": "verified",
        "en_words_quota": 1500,
        "actual_words": 1717,
        "sources_count": 12,
        "unverified_count": 1,
        "critical_count": 1,
        "verified_at": "2026-04-21T07:30:00Z",
        "verifier_verdict": "PASS-WITH-NOTES",
        "verifier_notes": "CRITICAL: 3-4 global supplier count needs qualification; Yeasen partial GMP foothold acknowledged; mandatory QC enzyme set framing should be workflow-dependent not compendial"
      },
      {
        "index": 8,
        "status": "verified",
        "en_words_quota": 1650,
        "actual_words": 1710,
        "sources_count": 15,
        "unverified_count": 3,
        "critical_count": 1,
        "verified_at": "2026-04-21T08:30:00Z",
        "verifier_verdict": "PASS-WITH-NOTES",
        "verifier_notes": "CRITICAL: C07 LNA claim narrowed — Hongene has LNA catalog; DMF absence is inferred not confirmed. NittoPhase 40% cost claim needs softening. APAC CAGR = 7.43%-15.2% range."
      },
      {
        "index": 9,
        "status": "verified",
        "en_words_quota": 1200,
        "actual_words": 1533,
        "sources_count": 12,
        "unverified_count": 0,
        "critical_count": 0,
        "verified_at": "2026-04-21T08:30:00Z",
        "verifier_verdict": "PASS-WITH-NOTES",
        "verifier_notes": "NMPA 2026 FINAL confirmed. Cu parenteral PDE = 300 µg/day confirmed (30 µg/day is inhalation). FDA 'no guidance' needs narrowing. EMA §4.2.2 confirms Q13 but says enzymatic synthesis 'too premature'. BIOSECURE count = 1."
      },
      {
        "index": 10,
        "status": "verified",
        "en_words_quota": 1350,
        "actual_words": 1547,
        "sources_count": 0,
        "sources_cross_chapter": 41,
        "unverified_count": 0,
        "critical_count": 2,
        "verified_at": "2026-04-21T09:15:00Z",
        "verifier_verdict": "PASS-WITH-NOTES",
        "verifier_notes": "CRITICAL: (1) Ranking criterion must be stated as time-to-revenue not strategic attractiveness to resolve Priority 4 apparent contradiction. (2) GT reuse threshold ≥10 cycles overstated — should be '≥6 cycles demonstrated; commercial target ≥10 cycles'. All three key corrections applied correctly: Cu PDE=300µg/day, ECO=strand-only, GT TRL=5-6."
      }
    ],
    "batches_summary": [
      {
        "batch": 1,
        "chapters": [
          1
        ],
        "completed_at": "2026-04-21T06:00:00Z",
        "summary": "Ch1 (1124 words, 10 new sources src_E01-E10, 2 unverified: GalNAc cycle-time claim + 3x QC-enzyme demand inference). 1 CRITICAL: draft overstates unimolecular dual-target superiority vs. cocktail; dr-analyst in Ch2/10 must balance."
      },
      {
        "batch": 2,
        "chapters": [
          2,
          3,
          4
        ],
        "completed_at": "2026-04-21T06:33:54Z",
        "summary": "Ch2 (1551 words, 18 sources, 0 unverified) — four design paradigms. Ch3 (1586 words, 17 sources) — global pipeline + China velocity. Ch4 (2113 words, 21 sources) — SPPS ceiling + AJIPHASE/CPOS/ECO benchmarks. All verified, no CRITICAL."
      },
      {
        "batch": 3,
        "chapters": [
          5,
          6,
          7
        ],
        "completed_at": "2026-04-21T07:30:00Z",
        "summary": "Ch5 (1701w, PASS-WITH-NOTES) CRITICAL: Cu parenteral PDE=300µg/day (not 30). Ch6 (1666w, PASS-WITH-NOTES) CRITICAL: ECO=strand-only not GalNAc; GT TRL→4-5. Ch7 (1717w, PASS-WITH-NOTES) CRITICAL: 3-4 supplier count needs per-enzyme caveat; Yeasen partial GMP."
      },
      {
        "batch": 4,
        "chapters": [
          8,
          9
        ],
        "completed_at": "2026-04-21T08:30:00Z",
        "summary": "Ch8 (1710w, PASS-WITH-NOTES) CRITICAL: LNA claim narrowed (Hongene has LNA catalog; no DMF is inferred not confirmed). NittoPhase 40% cost softened. Ch9 (1533w, PASS-WITH-NOTES) NMPA 2026 FINAL confirmed. Cu PDE=300µg/day reconfirmed. FDA no general oligo CMC guidance. EMA §4.2.2 confirms Q13."
      },
      {
        "batch": 5,
        "chapters": [
          10
        ],
        "completed_at": "2026-04-21T09:15:00Z",
        "summary": "Ch10 (1547w, PASS-WITH-NOTES) Synthesis chapter: 41 cross-chapter citations, 0 new sources. CRITICAL: (1) Ranking criterion must be explicit (time-to-revenue). (2) GT reuse threshold ≥10 cycles overstated vs Ch6 evidence (4-6 cycles demonstrated). All three key corrections applied correctly."
      }
    ]
  },
  "phase2_word_stats": {
    "total_en_words": 16248,
    "target_en_words": 15000,
    "min_en_words": 12000,
    "ratio": 1.083,
    "verdict": "合格 — 16,248 words / target 15,000 words (108.3%)",
    "estimated_zh_chars": 22747,
    "sources_unique": 44,
    "sources_tier1": 14,
    "sources_tier2": 25,
    "sources_tier3": 5,
    "unverified_claims_remaining": 3,
    "critical_flags_in_evidence": 10,
    "chapter_breakdown": [
      {
        "ch": 1,
        "words": 1124,
        "quota": 1050,
        "ratio": 1.07
      },
      {
        "ch": 2,
        "words": 1551,
        "quota": 1500,
        "ratio": 1.03
      },
      {
        "ch": 3,
        "words": 1586,
        "quota": 1500,
        "ratio": 1.06
      },
      {
        "ch": 4,
        "words": 2113,
        "quota": 1800,
        "ratio": 1.17
      },
      {
        "ch": 5,
        "words": 1701,
        "quota": 1800,
        "ratio": 0.95
      },
      {
        "ch": 6,
        "words": 1666,
        "quota": 1650,
        "ratio": 1.01
      },
      {
        "ch": 7,
        "words": 1717,
        "quota": 1500,
        "ratio": 1.14
      },
      {
        "ch": 8,
        "words": 1710,
        "quota": 1650,
        "ratio": 1.04
      },
      {
        "ch": 9,
        "words": 1533,
        "quota": 1200,
        "ratio": 1.28
      },
      {
        "ch": 10,
        "words": 1547,
        "quota": 1350,
        "ratio": 1.15
      }
    ]
  },
  "phase3": {
    "status": "completed",
    "approved": true,
    "approved_at": "2026-04-21T08:11:19Z",
    "approved_note": "User invoked /dr-finalize; dr-editor-in-chief accepts B rating and will integrate Must-Fix corrections during Phase 4 merge",
    "rating": "B",
    "critique_path": "projects/dual-target-rnai-pipeline-2026/phase3/critique.md",
    "must_fix_items": 5,
    "must_fix_addressed_in": "phase4/editorial-notes.md (to be created by dr-editor-in-chief)"
  },
  "phase4": {
    "status": "in_progress",
    "started_at": "2026-04-21T08:11:19Z",
    "stage": "translating",
    "merge_completed_at": "2026-04-21T08:17:29Z",
    "final_en_words": 19038,
    "final_en_path": "projects/dual-target-rnai-pipeline-2026/phase4/final_en.md",
    "editorial_notes_path": "projects/dual-target-rnai-pipeline-2026/phase4/editorial-notes.md"
  }
}